Skip to main content

Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.

Publication ,  Journal Article
Raghu, G; Collard, HR; Anstrom, KJ; Flaherty, KR; Fleming, TR; King, TE; Martinez, FJ; Brown, KK
Published in: Am J Respir Crit Care Med
June 1, 2013

Duke Scholars

Published In

Am J Respir Crit Care Med

DOI

EISSN

1535-4970

Publication Date

June 1, 2013

Volume

187

Issue

11

Start / End Page

1272

Location

United States

Related Subject Headings

  • Respiratory System Agents
  • Respiratory System
  • Idiopathic Pulmonary Fibrosis
  • Humans
  • Endpoint Determination
  • Clinical Trials, Phase III as Topic
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., … Brown, K. K. (2013). Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med, 187(11), 1272. https://doi.org/10.1164/rccm.201304-0712LE
Raghu, Ganesh, Harold R. Collard, Kevin J. Anstrom, Kevin R. Flaherty, Thomas R. Fleming, Talmadge E. King, Fernando J. Martinez, and Kevin K. Brown. “Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.Am J Respir Crit Care Med 187, no. 11 (June 1, 2013): 1272. https://doi.org/10.1164/rccm.201304-0712LE.
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, et al. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1272.
Raghu, Ganesh, et al. “Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.Am J Respir Crit Care Med, vol. 187, no. 11, June 2013, p. 1272. Pubmed, doi:10.1164/rccm.201304-0712LE.
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1272.

Published In

Am J Respir Crit Care Med

DOI

EISSN

1535-4970

Publication Date

June 1, 2013

Volume

187

Issue

11

Start / End Page

1272

Location

United States

Related Subject Headings

  • Respiratory System Agents
  • Respiratory System
  • Idiopathic Pulmonary Fibrosis
  • Humans
  • Endpoint Determination
  • Clinical Trials, Phase III as Topic
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 11 Medical and Health Sciences